Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy (pages 2004–2009)
Carlotta Sacerdote, Simonetta Guarrera, Fulvio Ricceri, Barbara Pardini, Silvia Polidoro, Alessandra Allione, Rossana Critelli, Alessia Russo, Angeline S. Andrew, Yuanqing Ye, Xifeng Wu, Lambertus A. Kiemeney, Andrea Bosio, Giovanni Casetta, Giuseppina Cucchiarale, Paolo Destefanis, Paolo Gontero, Luigi Rolle, Andrea Zitella, Dario Fontana, Paolo Vineis and Giuseppe Matullo
Version of Record online: 25 APR 2013 | DOI: 10.1002/ijc.28186
While several studies have investigated the role of DNA repair genetic variants in cancer susceptibility, only few investigated their role in survival and response to chemotherapy for bladder cancer. The present study looked at the association between 28 SNPs in eight DNA repair genes and survival from bladder cancer in 456 bladder cancer patients. When receiving chemotherapy, patients who presented a higher number of genetic variants in the XRCC1 base-excision repair gene had a better survival, suggesting that proficient DNA repair results in resistance to therapy and shorter survival. This finding may have clinical implications for the choice of therapy.